Login to Your Account

J&J prospects for gold in array of new deals

By Michael Fitzhugh
Staff Writer

Thursday, January 5, 2017

Johnson & Johnson Innovation LLC is opening 2017 with a blizzard of new deals, touching depression, cancer, diabetes, obesity and more. Highlights among the deals include an option to buy Bird Rock Bio Inc. following a phase I readout for its non-alcoholic steatohepatitis candidate, namacizumab.

To continue reading subscribe now to Latest News

Learn More about Latest News

Already a subscriber? Sign In or Buy now to activate your subscription